New hope: expanded access to cemiplimab for patients with advanced solid tumors
NCT ID NCT06132191
First seen Nov 20, 2025 · Last updated May 16, 2026 · Updated 21 times
Summary
This program provides expanded access to cemiplimab, a cancer immunotherapy, for patients with certain solid tumors like non-small cell lung cancer, basal cell carcinoma, and cutaneous squamous cell carcinoma. It is designed for people who cannot join a clinical trial and have no other treatment options. The goal is to offer this medication to control the disease and improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.